Modernizing cell therapy manufacturing to reduce vein-to-vein times
July 26, 2023
David Backer, CEO Curate Biosciences
Charlotte Barker (Editor, BioInsights) speaks with Curate Biosciences’ CEO David Backer and CTO Tony Ward about the need for CAR-T cell therapy manufacturing to evolve, and how a new cell separation technique could boost efficiency.
How have you seen CAR-T cell therapies evolve over time?
What are the key challenges and priorities for CAR-T cell manufacture?
Why are the initial steps in apheresis or debulking important?
How does DCS microfluidics differ from other techniques?
How can DCS optimize the expansion of T cells?
Does cell separation impact subsequent genome editing steps?
Can manufacturing processes help ensure clinical efficacy?